Why Your Brain Might Be Hijacking Your Wakefulness: Understanding Hypersomnia and Narcolepsy

Excessive daytime sleepiness (EDS) is more than just feeling tired—it can be a debilitating symptom of two distinct neurological disorders: hypersomnia and narcolepsy. While both conditions share the hallmark of…

Continue Reading Why Your Brain Might Be Hijacking Your Wakefulness: Understanding Hypersomnia and Narcolepsy
The Assistance Fund Offers New Financial Assistance Program for People with Idiopathic Hypersomnia (IH)
HeatherPaque / Pixabay

The Assistance Fund Offers New Financial Assistance Program for People with Idiopathic Hypersomnia (IH)

As many people within the rare disease community know, a rare disease diagnosis can come with a significant financial burden. Additionally, the costs, treatments, equipment, and other needs are not…

Continue Reading The Assistance Fund Offers New Financial Assistance Program for People with Idiopathic Hypersomnia (IH)
Serdexmethylphenidate for Idiopathic Hypersomnia Earns Orphan Drug Designation
https://pixabay.com/en/toddler-boy-sleeping-child-1245674/

Serdexmethylphenidate for Idiopathic Hypersomnia Earns Orphan Drug Designation

  In the United States, the FDA grants Orphan Drug designation to drugs or biologics intended to treat, diagnose, or prevent rare diseases or conditions. A rare disease is one…

Continue Reading Serdexmethylphenidate for Idiopathic Hypersomnia Earns Orphan Drug Designation
Xywav for Idiopathic Hypersomnia Earns Orphan Drug Exclusivity
https://pixabay.com/en/baby-girl-sleep-child-toddler-1151351/

Xywav for Idiopathic Hypersomnia Earns Orphan Drug Exclusivity

Orphan Drug designation is typically granted to drugs or biologics intended to treat, prevent, or diagnose rare diseases; in the United States, these are conditions affecting under 200,000 Americans. Drug…

Continue Reading Xywav for Idiopathic Hypersomnia Earns Orphan Drug Exclusivity

Xywav for Idiopathic Hypersomnia Receives Priority Review and sNDA Acceptance

In a news release from April 2021, biopharmaceutical company Jazz Pharmaceuticals, Inc. ("Jazz") shared that the FDA accepted its supplemental New Drug Application (sNDA) for review in relation to Xywav,…

Continue Reading Xywav for Idiopathic Hypersomnia Receives Priority Review and sNDA Acceptance

The Hypersomnia Foundation’s Educational Meeting

  • Post author:
  • Post category:

The HF Educational Meeting Seattle, Oregon The conference will be an opportunity for patient families and medical experts to meet and learn about the latest in idiopathic research. Additionally, families…

Continue Reading The Hypersomnia Foundation’s Educational Meeting